US2020040074A1PendingUtilityA1

Antibodies to il-6 and use thereof

Assignee: ALDERBIO HOLDINGS LLCPriority: May 21, 2007Filed: Mar 18, 2019Published: Feb 6, 2020
Est. expiryMay 21, 2027(~0.8 yrs left)· nominal 20-yr term from priority
A61P 35/00C12N 15/81C12P 21/02C07K 2317/41A61K 2039/505C12N 9/64C07K 2317/92C12N 9/60C07K 2317/34C07K 2317/24C07K 2317/565C07K 2317/56C07K 16/248C07K 2317/76A61K 39/3955
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Claims

exact text as granted — not AI-modified
1 . An anti-human IL-6 antibody or antibody fragment which specifically binds to the same linear or conformational epitope(s) and/or competes for binding to the same linear or conformational epitope(s) on an intact human IL-6 polypeptide or fragment thereof as an anti-human IL-6 antibody selected from the group consisting of Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13, Ab14, Ab15, Ab16, Ab17, Ab18, Ab19, Ab20, Ab21, Ab22, Ab23, Ab24, Ab25, Ab26, Ab27, Ab28, Ab29, Ab30, Ab31, Ab32, Ab33, Ab34, Ab35, and Ab36 or an anti-IL-6 antibody containing the variable light region contained in any one of the SEQ ID NO:647-651 and a variable heavy chain region contained in any one of SEQ ID NO:s 652-658. 
     
     
         2 - 137 . (canceled)

Join the waitlist — get patent alerts

Track US2020040074A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.